What is ALKS's P/E ratio?

ALKERMES PLC (ALKS) currently trades at a P/E ratio of 63.30.

ALKERMES PLC reports a Return on Equity (ROE) of 3.66%.

What is ALKS's dividend yield?

ALKERMES PLC offers a dividend yield of 0.00%.

What is ALKS's Quality Score?

Our AI rates ALKS's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ALKS?

Our AI Timing Score for ALKS is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ALKS belong to?

ALKERMES PLC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

ALKS (NASDAQ) Stock Analysis | ALKERMES PLC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

ALKS AI Analysis Summary

Our AI summary for ALKS: ALKERMES PLC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 63.30, ROE of 3.66%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ALKS

ALKERMES PLC

USD 48.99

-1.04 (-2.08%) Day Change

Watchlist Portfolio Compare Chart

63.30

P/E

0.02

D/E

3.7%

ROE

1.5%

ROA

0.00%

Div Yield

-0.55

PEG

ALKERMES PLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 48.99 Price -1.04 (-2.08%) Day Change	NEWS SCORE: 91

ALKS, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	1868
Magic Formula Rank by ROE	1868
Magic Formula Rank by ROIC	1538
Price	48.99
PBV / Sector	4.64 / 3.22
Earning Per Share	0.39

PE / Sector	63.30 / 29.79
PEG or PE/Growth / Sector	-0.55 / 0.13
Average 1M Daily Value	91.66 M
Average 1W Daily Value	119.80 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

58%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	3.97 / 15.21
NPM Average (%) / Sector	10.21 / -10.83 GOOD
NPM Change Average (%) / Sector	-86.59 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	1.51 / 8.15
ROA Average (%) / Sector	7.50 / 2.87
ROA Change Average (%) / Sector	-107.55 / 112.70
ROE (%) / Sector	3.66 / -1.02
ROE Average (%) / Sector	11.28 / 8.35
ROE Change Average (%) / Sector	-107.46 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 07:59:27
Symbol	ALKS
Name	ALKERMES PLC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	167.76 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	8,393.20 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Connaught House, Dublin, Ireland, D04 C5Y6

Phone: 353 1 772 8000

Website: https://www.alkermes.com

Employees: 2,050

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.